5:48 PM
 | 
Oct 22, 2013
 |  BC Extra  |  Clinical News

Xtandi meets in chemotherapy-naïve CRPC patients

Medivation Inc. (NASDAQ:MDVN) and partner Astellas Pharma Inc. (Tokyo:4503) stopped early the Phase III PREVAIL trial on the recommendation of an independent DMC after an interim analysis showed enzalutamide met the co-primary endpoints in chemotherapy-naïve metastatic castration-resistant prostate cancer...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >